| Open |
S2001 |
Parallel Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib as Maintenance Therapy in Two Cohorts of Metastatic Pancreatic Cancer Patients with DNA Damage Repair Defects |
12/4/2020 |
|
67% |
|
|
| Closed |
S0437 |
PCPT Long Term Follow Up |
9/1/2005 |
3/1/2009 |
53% |
|
|
| Closed |
S0224 |
Penile |
10/15/2004 |
11/15/2005 |
5% |
|
|
| Closed |
S1505 |
Perioperative FOLFIRINOX vs Gem/nab-Pac for Resectable Panc Adeno |
10/12/2015 |
|
98% |
|
|
| Closed |
S9909 |
PET Imaging Ancillary to S9900 in NSCLC |
12/15/1999 |
5/15/2001 |
1% |
|
|
| Closed |
S0905 |
Ph I / Randomized Ph II Mesothelioma Cediranib |
3/15/2010 |
2/15/2016 |
91% |
|
Published
|
| Closed |
S1313 |
Ph Ib/II Rando mFOLFIRINOX+PEGPH20 vs mFOLFIRINOX Alone in Good PS Met Pancreatic Adenocarcinoma |
1/6/2014 |
|
73% |
|
|
| Closed |
S1702 |
Ph II AL amyloidosis isatuximab |
3/8/2018 |
9/30/2019 |
100% |
|
|
| Closed |
S1605 |
Ph II Atezolizumab Local Bladder |
2/7/2017 |
|
85% |
|
|
| Closed |
S1416 |
Ph II Cisplatin +/- ABT 888 in Metastatic TNBC and/or BRCA |
7/7/2016 |
6/15/2019 |
100% |
|
|
| Open |
S2114 |
Ph II consolidation therapy following CD19 CAR-T for R/R DLBCL or Gr III FL |
2/23/2023 |
|
22% |
|
|
| Closed |
S1005 |
Ph II MK-2206 gastric and GEJ |
1/1/2011 |
5/1/2013 |
100% |
|
Published
|
| Closed |
S1801 |
Ph II Ramdomization for Clinically Detectable Stage III-IV High-risk Melanoma |
12/6/2018 |
5/5/2022 |
100% |
|
|
| Closed |
S0713 |
Ph II Rectal Pre-Operative ChemoRT |
2/1/2009 |
4/15/2013 |
94% |
|
Published
|
| Closed |
S1507 |
Ph II Tram + doce with kras NSCLC + and PD |
7/18/2016 |
3/15/2018 |
100% |
|
|
| Open |
S1918 |
Ph II/III study of R-miniCHOP +/- oral aza in elderly with newly diganosed DLBCL |
3/19/2021 |
|
29% |
|
|
| Closed |
S0927 |
Ph III Omega-3 fatty acid/placebo Breast Cancer |
2/1/2012 |
2/1/2013 |
100% |
|
Published
|
| Closed |
S1202 |
Ph III Study of Duloxetine for AI-associated musculoskleteal symptoms for Early Stage BrCa |
5/15/2013 |
10/1/2015 |
100% |
|
Published
|
| Closed |
S1222 |
Ph. III Randomized Trial of fulvestrant +/- exemestane +/- everolimus in HR+ postmenopausal Stage IV |
5/9/2014 |
10/15/2015 |
4% |
|
|
| Closed |
S1207 |
Ph. III Randomized, Everolimus in high risk, hormone receptor positive, HER2 negative patients. |
9/3/2013 |
5/1/2019 |
100% |
|
|
